ePT--the Electronic Newsletter of Pharmaceutical Technology, Jun 2, 2011 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe
ePT--the Electronic Newsletter of Pharmaceutical Technology, Jun 2, 2011
News
FDA Unveils Inspections Database
By Erik Greb
FDA added a searchable database of inspection data to its website. The database lists the names and addresses of facilities that the agency inspected during fiscal years 2009 and 2010.
Mylan Plans Direct Entry Into Indian Market
By Amy Ritter
Mylan, a generic-drug manufacturer, announced that it will be rebranding its Hyderabad, India-based subsidiary, Matrix Laboratories, as Mylan.
Independent Expert Advises EMA on Benefit/Risk Communication
By Rich Whitworth
An independent report released by the European Medicines Agency highlighted a number of recommendations to aid the agency in its communication of the benefits and risks of medicines.
WHO Meets to Discuss Global Health Policy
By Patricia Van Arnum
During an eight-day series of meetings that concluded on May 24, 2011, the World Health Assembly passed 28 resolutions and adopted three decisions to guide the organization?s work and address global health issues.
Capgemini: Pharma Must Act Against Patient Noncompliance
By Stephanie Sutton
The pharmaceutical industry has been called to action by a new report that highlights the health and cost repercussions of patient noncompliance.
Week of June 2, 2011: Company and People Notes: Valeant agrees to acquire Sanitas Group; Geron makes several senior appointments; and More.
Valeant agrees to acquire Sanitas Group; Geron makes several senior appointments; and More.

ADVERTISEMENT
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
21%
To all process for new products only
11%
To select process for new products only
25%
To select processes for both new and legacy products
21%
Do not use QbD
23%
View Results
Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
FindPharma Custom Search
Featured Jobs

More Jobs
Click here